NRBO:NSD-Neurobo Pharmaceuticals Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 4.4702

Change

0.00 (0.00)%

Market Cap

USD 0.05B

Volume

0.03M

Analyst Target

USD 25.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-07-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

-8.59 (-1.86%)

USD 119.56B
REGN Regeneron Pharmaceuticals Inc

-25.68 (-2.47%)

USD 114.65B
ALNY Alnylam Pharmaceuticals Inc

-2.02 (-0.74%)

USD 35.44B
ARGX argenx NV ADR

-7.01 (-1.27%)

USD 32.73B
MRNA Moderna Inc

-2.09 (-3.31%)

USD 25.27B
BGNE BeiGene Ltd

+0.04 (+0.02%)

USD 24.38B
RPRX Royalty Pharma Plc

-0.49 (-1.74%)

USD 16.72B
UTHR United Therapeutics Corporatio..

-2.40 (-0.68%)

USD 15.95B
SMMT Summit Therapeutics PLC

-0.93 (-4.76%)

USD 15.35B
PCVX Vaxcyte Inc

-3.17 (-2.77%)

USD 14.00B

ETFs Containing NRBO

GREK Global X MSCI Greece ETF 0.00 % 0.59 %

-0.53 (-1.26%)

USD 0.21B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 20.91% 78% C+ 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 20.91% 78% C+ 83% B
Trailing 12 Months  
Capital Gain 27.28% 80% B- 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.28% 80% B- 81% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -58.34% 1% F N/A F
Dividend Return -58.34% 1% F N/A F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 63.28% 44% F 25% F
Risk Adjusted Return -92.19% 15% F 8% B-
Market Capitalization 0.05B 34% F 27% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.